Nanotechnology-enabled miRNA delivery systems next-generation molecular strategies in cancer therapy

Basit Öğe Kaydı
dc.contributor.authorKuran, Sara Azra
dc.contributor.authorAdiyil, Rumeysa
dc.contributor.authorZiksahna, Kaan
dc.contributor.authorOzkan, Melisa
dc.contributor.authorIhlamur, Murat
dc.date.accessioned2026-01-24T12:31:07Z
dc.date.available2026-01-24T12:31:07Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractMicroRNAs (miRNAs) regulate cancer-relevant pathways but are limited clinically by instability, immune activation, and inefficient uptake. Nanotechnology offers platforms that protect and target miRNAs to tumors while enabling controlled release and intracellular delivery. This review focuses on lipid-based systems (including functionalized lipid nanoparticles (LNPs)), polymeric nanoparticles, dendrimers, and responsive hydrogels/ nanogels, emphasizing comparative performance and translational readiness. We outline key barriers-enzymatic degradation, rapid clearance, endosomal trapping, off-target effects, and manufacturability-and highlight practical solutions such as poly (ethylene glycol) (PEG) coating (PEGylation)/stealthing to prolong circulation, ligand-directed targeting to enhance specificity, ionizable/fusogenic chemistries for endosomal escape, and standardized evaluation to improve reproducibility. Recent preclinical studies illustrate meaningful antitumor activity and improved tolerability for several platforms, while clinical experiences underscore the need for rigorous safety assessment and scalable production. We conclude with a concise roadmap that prioritizes platform selection for near-term translation and integration with tumor-specific miRNA signatures to advance personalized therapy. Our translation-first synthesis links barriers to design solutions (pKatuned LNPs; exosome-mimetic/hybrid vesicles) and highlights AI/ML-guided formulation; lessons from MRX34/ TargomiRs inform safety, scalability, and CMC-together yielding a practical 24-36-month roadmap toward clinical readiness, with functionalized LNPs best positioned for near-term translation.
dc.identifier.doi10.1016/j.bbrc.2025.152923
dc.identifier.issn0006-291X
dc.identifier.issn1090-2104
dc.identifier.pmid41242300
dc.identifier.scopus2-s2.0-105021480513
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.bbrc.2025.152923
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5647
dc.identifier.volume792
dc.identifier.wosWOS:001621757200002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofBiochemical and Biophysical Research Communications
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectmicroRNA
dc.subjectNanotechnology
dc.subjectCancer therapy
dc.subjectNanocarriers
dc.subjectTargeted delivery
dc.titleNanotechnology-enabled miRNA delivery systems next-generation molecular strategies in cancer therapy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu